Oral presentation at the Oxford Global Immuno 2024 congress
Targeting the CD47-SIRPα myeloid checkpoint by BYON4228 25 April 2024Byondis’ Senior Director Immuno-Oncology and original discoverer of the CD47-SIRPα immune checkpoint Timo van den Berg will present at Immuno 2024 on our investigational anti SIRPα antibody BYON4228. He will discuss the discovery of the CD47-SIRPα checkpoint, considerations for targeting CD47-SIRPα and the development of BYON4228.
